01—Abstract
Summary
Summary of the 10-K filed February 21, 2024. Cited figures are marked; the original filing is the authoritative source.
Eli Lilly and Company (LLY) reported strong performance in its 2023 10-K filing, driven by significant growth in key therapeutic areas, particularly diabetes, obesity, and oncology.
Revenue increased by 20%a year-over-year, with notable contributions from Mounjaro, Verzenio, and Jardiance. The company is heavily investing in its late-stage pipeline, with approximately 50 new medicine candidates in clinical development or under regulatory review, including promising treatments for Alzheimer's disease (Donanemab) and obesity. This robust pipeline, coupled with strategic acquisitions like POINT Biopharma for radiopharmaceutical capabilities, positions Lilly for continued innovation and market leadership.
However, the company faces ongoing challenges including intense competition, increasing government price controls (like those from the Inflation Reduction Act), and supply chain complexities for high-demand products like Mounjaro and Trulicity. Despite these headwinds, Lilly's strategic focus on innovation and expansion of manufacturing capacity provides a foundation for future growth, though investors should monitor regulatory developments and competitive pressures.
02—Key points
Key Highlights
- Revenue increased 20% year-over-year to $34.1 billion, driven by strong sales of Mounjaro, Verzenio, and Jardiance.
- The company has a robust late-stage pipeline with approximately 50 new medicine candidates in clinical development or under regulatory review, including significant advancements in Alzheimer's (Donanemab) and obesity treatments.
- Strategic acquisitions, including POINT Biopharma for radiopharmaceuticals, DICE Therapeutics for immunology, and Versanis Bio for obesity, demonstrate Lilly's commitment to expanding its therapeutic reach and innovation capabilities.
- Despite increased R&D spending (up 30% to $9.3 billion), net income decreased by 16% to $5.2 billion, largely due to higher acquired R&D charges and operating expenses.
- Significant supply chain challenges and intermittent delays are being experienced for high-demand incretin products (Mounjaro and Trulicity) due to a mismatch between demand and manufacturing capacity, though the company is actively expanding production.
- Lilly faces ongoing risks from government price controls, particularly the Inflation Reduction Act, which could impact future revenue streams for key products like Jardiance.
- The company declared a quarterly dividend of $1.30 per share, an increase from previous periods, reflecting confidence in its financial stability and cash generation.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2023filed February 21, 2024Financial Statements
FY2023 against FY2022
| Line item | FY2023FY2022 | Change |
|---|---|---|
| Revenue | $34.12B$28.54B | +19.6% |
| Cost of Revenue | $7.08B$6.63B | +6.8% |
| Gross Profit | $27.04B$21.91B | +23.4% |
| SG&A Expenses | $7.40B$6.44B | +15.0% |
| Interest Expense | $485.90M$331.60M | +46.5% |
| Net Income | $5.24B$6.24B | −16.1% |
| EPS (Basic) | $5.82$6.93 | −16.0% |
| EPS (Diluted) | $5.80$6.90 | −15.9% |
| Shares Outstanding (Basic) | 900.20M901.74M | −0.2% |
| Shares Outstanding (Diluted) | 903.30M904.62M | −0.1% |
05—Questions
Frequently Asked Questions
What were Eli Lilly's key drivers of revenue growth in 2023?
Eli Lilly's revenue grew by 20% in 2023, primarily driven by increased volume and higher realized prices. Key products contributing to this growth included Mounjaro, Verzenio, Jardiance, and Taltz. The sale of rights for the olanzapine portfolio (Zyprexa) and Baqsimi also contributed significantly to the revenue increase.
What is the status of Eli Lilly's pipeline, particularly for Alzheimer's and obesity treatments?
Lilly has a strong late-stage pipeline with about 50 new medicine candidates. For Alzheimer's, Donanemab has been submitted for regulatory review in the U.S., EU, and Japan. In the obesity and diabetes space, tirzepatide (Mounjaro/Zepbound) continues to see strong demand and expanded indications, with several Phase III trials ongoing. New obesity candidates like orforglipron and retatrutide are also progressing through late-stage development.
What are the main risks and challenges Eli Lilly highlighted in its 10-K?
Lilly highlighted several key risks, including intense competition from other pharmaceutical and generic/biosimilar manufacturers, the high cost and uncertainty of pharmaceutical R&D, increasing government price controls and reimbursement pressures (notably the Inflation Reduction Act), and potential supply chain disruptions for high-demand products. The company also faces risks related to intellectual property protection, litigation, and cybersecurity.
How is Eli Lilly managing its manufacturing capacity for high-demand products like Mounjaro and Trulicity?
Eli Lilly is experiencing significant demand for its incretin products, leading to intermittent delays in fulfilling orders. The company is actively addressing this by investing heavily in expanding its manufacturing capabilities, both internally and through contract manufacturers, with new capacity expected to become operational globally over the next several years. Despite these efforts, tight supply is expected to persist until this new capacity is fully utilized.
06—Continue